IGC Pharma (IGC) Q4 2025 earnings summary

Executive summary

• Lead asset IGC81 (also referred to as IGC-AD1) advanced in phase II trials for agitation in Alzheimer's, showing rapid onset and significant efficacy, with expansion of clinical trial sites across North America to accelerate enrollment and access diverse populations.

• AI-driven diagnostic platform MINT-AD developed for early detection and risk stratification of Alzheimer's, recognized by NIH, NIA, and awarded in the PREPARE Challenge.

• Pipeline expanded to include GLP-1 agonist candidates, targeting neurodegenerative and metabolic disorders, and broadened research to address cognitive impairment and Alzheimer's pathology.

• Focused on efficient capital deployment, minimizing dilution, and aligning management incentives with shareholders through performance-based compensation.

• Achieved significant clinical milestones and innovation in Alzheimer's research, with recognition for AI integration in diagnostics.

Financial highlights

• Renewed $12 million line of credit and extended loan agreement to support operations.

• Fiscal 2025 revenue decreased to $1.2M from $1.3M, mainly due to the end of infrastructure business, while Life Sciences segment revenue increased to $1.27M.

• SG&A expenses dropped 35% to $4.4M, and R&D expenses were $3.7M, down 3% from $3.8M.

• Clinical trial costs managed at approximately half the industry average per patient due to in-house CRO.

• Net loss improved to $7.1M ($0.09/share) from $13M ($0.22/share) year-over-year.

Outlook and guidance

• Phase II trial for agitation in Alzheimer's expected to complete by March next year, with no further interim data planned.

• Plans to launch a second phase II trial for IGC81 as a disease-modifying therapy, targeting late calendar year 2025.

• Continued development and deployment of MINT-AD, with beta version operational and further updates anticipated throughout the year and into Fiscal 2026.

• Anticipates increased R&D spending as resources shift to TGR-63 and ongoing trials.

• Committed to long-term value creation and accelerating Alzheimer's breakthroughs.